Eli Lilly’s blowout quarter should quiet investor concerns about the stock

Earnings

Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023. 
George Frey | Bloomberg | Getty Images

Eli Lilly on Thursday reported a home-run quarter fueled by sales of its blockbuster obesity and diabetes drugs, quieting any lingering investor concerns in the stock.

Articles You May Like

Crypto investor pays $6 million for a banana — and plans to eat it
Here’s how to leverage the 0% capital gains bracket as the price of bitcoin surges
TJ Maxx parent says holiday shopping is off to a ‘strong start,’ but its guidance tells another story
Walmart may have to raise some prices if Trump tariffs take effect, CFO says
Snowflake rockets 32%, its best day ever, after earnings beat

Leave a Reply

Your email address will not be published. Required fields are marked *